文献速递胃肠外科急腹症与外科感染

抗生素对比安慰剂治疗CT确诊的无并发症急性阑尾炎(APPAC III):随机双盲优效性试验

Antibiotics versus placebo in adults with CT-confirmed uncomplicated acute appendicitis (APPAC III): randomized double-blind superiority trial.
PubMed 文献 · Br J Surg · 2022-01-01

该双盲安慰剂对照优效性随机对照试验纳入72例CT确诊的无并发症急性阑尾炎成人,比较抗生素(静脉厄他培南后口服左氧氟沙星联合甲硝唑)与安慰剂的10天治疗成功率,主要结局无统计学差异(1侧P=0.142)。结论提示需要开展非劣效性试验以评估无抗生素治疗轻度阑尾炎的可行性。

要点

  • 10天治疗成功率安慰剂组87%,抗生素组97%,差异无统计学意义。
  • 本研究仅达到预设三种情景中最低样本量,因入组困难提前终止。
  • 轻度与重度急性阑尾炎应视为两种不同疾病,重度仍需手术。

核心结论

  • 抗生素相比安慰剂在CT确诊的无并发症急性阑尾炎成人中未显示统计学优效性。
  • 作者认为有必要在CT确诊的轻度阑尾炎成人中开展安慰剂对照的非劣效性试验。

研究设计与样本

  • 双盲、安慰剂对照、优效性随机对照试验,在5家医院招募72例CT确诊的无并发症急性阑尾炎成人。
  • 随机后排除6例(5例早期撤回知情同意,1例违反随机化方案),最终抗生素组35例、安慰剂组31例。
  • 抗生素方案为静脉厄他培南后口服左氧氟沙星联合甲硝唑。
  • 主要终点为10天内无需阑尾切除即缓解出院的治疗成功,次要结局包括疼痛评分、并发症、住院时间和恢复工作。
  • 因入组困难仅达到预设三种情景中最低样本量。

主要发现

  • 10天治疗成功率:安慰剂组87%(95%CI 75%~99%),抗生素组97%(95%CI 92%~100%)。
  • 两组临床差异为10%(90%CI -0.9%~21%),主要结局无统计学差异(单侧P=0.142)。
  • 次要结局两组相似。

临床怎么用

  • 对于CT确诊的轻度急性阑尾炎,抗生素并非必需,部分病例可自行缓解。
  • 重度急性阑尾炎仍需阑尾切除,抗生素单独治疗仅作为轻度疾病的选择之一。
  • 目前证据尚不足以推荐常规省略抗生素,需等待更大样本的非劣效性试验结果。

局限性

  • 样本量小,仅达到预设最低样本量,可能不足以检测出有临床意义的差异。
  • 因入组困难(包括急诊外科环境下医院药房资源限制)提前终止,统计效能不足。
  • 研究结论需更大样本试验验证省略抗生素的安全性和非劣效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-operative management of uncomplicated acute appendicitis is an option, but omission of antibiotics from the regimen has not been tested. METHODS: A double-blind, placebo-controlled, superiority RCT in adults with CT-confirmed uncomplicated acute appendicitis was designed to compare placebo with antibiotics (intravenous ertapenem followed by oral levofloxacin and metronidazole). The primary endpoint was treatment success (resolution resulting in discharge without appendicectomy within 10 days); secondary outcomes included pain scores, complications, hospital stay, and return to work. RESULTS: From May 2017 to September 2020, 72 patients with a mean(s.d.) age of 37.5 (11.1) years were recruited at five hospitals. Six were excluded after randomization (5 early consent withdrawals, 1 randomization protocol violation), 35 were assigned to receive antibiotics, and 31 to receive placebo. Enrolment challenges (including hospital pharmacy resources in an acute-care surgery setting) meant that only the lowest sample size of three predefined scenarios was achieved. The 10-day treatment success rate was 87 (95 per cent c.i. 75 to 99) per cent for placebo and 97 (92 to 100) per cent for antibiotics. This clinical difference of 10 (90 per cent c.i. -0.9 to 21) per cent was not statistically different for the primary outcome (1-sided P = 0.142), and secondary outcomes were similar. CONCLUSION: The lack of antibiotic superiority statistically suggests that a non-inferiority trial against placebo is warranted in adults with CT-confirmed mild appendicitis. Registration number: EudraCT 2015-003634-26 (https://eudract.ema.europa.eu/eudract-web/index.faces), NCT03234296 (http://www.clinicaltrials.gov). Appendicitis was the most common reason for emergency surgery, but we now know that mild and severe acute appendicitis are two different diseases. Severe appendicitis still necessitates removal of the appendix but antibiotics alone are an option for mild disease. This small study found that most cases of mild appendicitis to resolve even without antibiotics. Larger studies (more patients) would be needed to show that omitting antibiotics is safe and no worse than antibiotic therapy for milder acute appendicitis.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Salminen P, Sippola S, Haijanen J, et al. Antibiotics versus placebo in adults with CT-confirmed uncomplicated acute appendicitis (APPAC III): randomized double-blind superiority trial. Br J Surg. 2022. PMID: 35576384. doi:10.1093/bjs/znac086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。